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UMBILICAL CORD BLOOD TRANSPLANTATION: STATE OF THE ART
Wagner, John E. Blood and Marrow Transplantation Program and
Stem Cell Institute, University of Minnesota, Minneapolis, MN.
Cryopreserved umbilical cord blood (UCB) has been investigated as
a potential strategy for augmenting the pool of acceptable donors,
reducing the risks of acute and chronic graft-versus-host disease
(GVHD) and improving survival. Cell dose, however, has clearly been
established as the most signiﬁcant limitation. To this end, multiple
strategies have been proposed to address cell dose, including use of
culture expanded UCB, co-infusion of haploidentical peripheral
blood, multiple units, co-infusion of mesenchymal stem cells, and
intra bone marrow injection. In addition, novel strategies to reduce
regimen related mortality (RRM) and enhance graft-versus-leukemia
have been explored. In anticipation of these presentations, the ex-
pected outcomes with the standard approach of myeloablation and
single UCB transplantation will be summarized.
At the University of Minnesota, 102 patients received cyclophos-
phamide 120 mg/kg, total body irradiation 1320-1375 cGy and
antithymocyte globulin 90 mg/kg with cyclosporine and short
course methylprednisolone immunoprophylaxis. Median age was
7.4 years and median cell dose was 3.1  107 nucleated cells/kg
(range 0.7-57.9) with 86% receiving a 1-3 HLA-antigen mis-
matched graft. Median time to neutrophil recovery was 23 days
(range 9-54) with 88% engrafting by day 42. Inferior engraftment
was observed in patients receiving a CD34 cell dose 1.7  105
cells/kg (72% at a median of 34 days). Incidence of grade II-IV and
grade III-IV acute GVHD was 39% (95% CI: 29-49) and 11%
(95% CI: 5-17), respectively, and incidence of chronic GVHD was
10% (95% CI: 4-14). RRM at 1 year was 30% (95% CI: 21-39)
with low CD34 cell dose and HLA disparity adversely affecting
outcome. At a median of 2.7 years, survival was 58% (95% CI:
49-70) at 1 year and 47% (95% CI: 36-57) at 2 years with 70%
(95% CI: 49-90) survival in patients receiving 1.7  105 CD34
cells/kg. In Cox regression, HLA match, CD34 cell dose and
development of grade III-IV acute GVHD risk factors. These data
highlight the limitations of UCB and serve to stimulate the next
generation of clinical trials.
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REDUCED-INTENSITY UNRELATED CORD BLOOD TRANSPLANTATION
FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES
Miyakoshi, Shigesaburo. Department or Hematology, Toranomon Hos-
pital, Tokyo, Japan.
Allogeneic stem cell transplantations (SCT) have been develop-
ing rapidly. Graft versus malignancy is the therapeutic component
of SCT so that myeloablation is not absolutely essential. Non-
myeloablative stem cell transplantation and transplantation with
reduced intensity (RI) conditioning have been developed. Eventu-
ally, we can combine many kinds of stem cell sources and condi-
tioning regimens.
In 2001 the clinical outcome of 2 patients with malignant lym-
phoma after reduced intensity stem cell transplantation (RIST)
with cord blood (RICBT) was ﬁrst reported by investigators at
Duke University. After this, several reports about RICBT were
published. These reports encouraged us to start RICBT. We have
already acquired valuable experience about RICBT for hemato-
logic malignancies.
In this symposium the results of RICBT for hematologic malig-
nancies in Toranomon Hospital will be summarized.
In our experience, this reduced intensity regimen and graft-
versus-host disease (GVHD) prophylaxis were almost certain to
lead to neutrophil, platelet and donor T cells engraftment. Inci-
dence of acute/chronic GVHD and overall survival (OS) were
acceptable, however treatment related mortality (TRM) was high.
Second, I will report the results of RICBT for adult acute lym-
phoblastic leukemia (ALL) and relapsed and refractory malignant
lymphomas (ML). As a matter of course OS and disease free
survival (DFS) were not so good, but RICBT would lead some
patients to cure. RICBT would be one of the strategies for cure of
ALL and ML. However, TRM after RICBT was the most impor-
tant problem for ML and ALL.
Third, I compared among related peripheral blood stem cell
transplantation (R-PBSCT), unrelated bone marrow transplanta-
tion (UBMT), and cord blood transplantation with reduced inten-
sity regimens for AM/MDS. The incidence of acute GVHD,
TRM, and OS were similar among these three stem cell sources
with reduced intensity regimens, but neutrophil and platelet en-
graftment were slower than R-PBSCT. Relapse rate over 100 days
in RICBT might be higher than for the others.
Finally, I will conclude that the most important problem after
RICBT is high TRM. We should consider new approaches to
decrease TRM after RICBT.
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REDUCED INTENSITY (RI) ALLOGENEIC CORD BLOOD HEMATOPOI-
ETIC CELL TRANSPLANTATION (ALLO-CBHCT) IN PEDIATRIC PATIENTS
WITH MALIGNANT AND NON-MALIGNANT DISEASES
Satwani, P.,1 Del Toro, G.,1 Bradley, M.,1 Morris, E.,1 van de Ven, C.,1
Cheung, Y.-K.,2 Yamashiro, D.,1 Garvin, J.,1 Bhatia, M.,1 Roman, E.,1
Schwartz, J.,3 Militano, O.,1 Cooney, E.,1 Wolownik, K.,1 Hawks, R.,1
Foley, S.,1 Cairo, M.S.1,3,4 Departments of 1Pediatrics, 2Biostatistics,
3Pathology, and 4Medicine, Columbia University, New York, NY.
There is a signiﬁcant amount of morbidity and mortality following
myeloablative CBHCT (Gluckman et al, NEJM 1997). RI condition-
ing may reduce regimen-related mortality (RRM) and the late effects
associated with myeloablative regimens without increasing the risk of
graft failure in children and adolescents (Del Toro et al, BMT 2004).
We report the results in 22 pediatric recipients, 6F:16M, median age
6.5 years (0.4-21 yrs). Twenty one received unrelated CBHCT, with
HLA matching of 4/6 (n  14), 5/6 (n  5), 6/6 (n  2); 1 sibling
CBHCT (6/6). Seventeen hadmalignant [HD (5), NHL (2), NBL (4),
AML (2), MDS(3), CML (1)], and 5 had non-malignant [-thal (1),
HLH (2), WAS (1), SCD (1)] diseases. RI conditioning was ﬂudara-
bine-based (150-180 mg/m2) with busulfan (8 mg/kg)  rabbit ATG
(n 17) and ﬂudarabine cyclophosphamide etoposideATG (n
 5). GHVD prophylaxis: tacrolimus and MMF (Osunkwo et al,
BBMT 2004). Median TNC count was 3.8 107/kg (0.92-10.82) and
CD34 count was 2.2  105/kg (0.34-7.0). The median day to WBC
engraftment was 19.5 (1-47) and to platelet engraftment was 40
(6-170) days. There were 6 primary graft failures (1 CML, 1 -Thal,
2 HLH, 1 MDS, 1 AML).The probability of developing grade II-IV
and III-IV aGVHD was 33.3% and 15%, respectively, and probability
of chronic GVHD was 20%. The probability of 3-year overall OS in
all patients was 63%. Despite a log less nucleated cells/kg with CB vs
PB or BM HCT, the 3-yr OS in standard-risk malignancy patients
was 90%. The 1-yr OS in poor-risk malignancy patients was 21%. In
conclusion, RI Allo CBHCT may result in more rapid hematopoietic
reconstitution while decreasing RRM compared to myeloablative CB-
HCT and may be associated with high mixed-donor chimerism.
Patients with non-malignant diseases may require increased intensity
of conditioning. Further follow-up is required to evaluate the long-
term effects following RI Allo-CBHCT.
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DOUBLE UMBILICAL CORD TRANSPLANTS (UCBT) WITH MYELOABLA-
TIVE OR REDUCED INTENSITY CONDITIONING REGIMENS (RIC)
Baker, K. Scott, Wagner, John E. Blood and Marrow Transplantation
Program and Stem Cell Institute, University of Minnesota, Minne-
apolis, MN.
Between 2000 and 2005, 143 consecutive patients received two
partially HLA matched UCB units to enhance engraftment. 50
patients [median age: 24 years (range: 11-60 years)] received cy-
clophosphamide (CY) 120 mg/kg, TBI 1320 cGy and ﬂudarabine
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